Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Nov 28, 2009; 15(44): 5598-5603
Published online Nov 28, 2009. doi: 10.3748/wjg.15.5598
Published online Nov 28, 2009. doi: 10.3748/wjg.15.5598
Table 1 Basic characteristics of subjects, stratified by HOMAIR (mean ± SD)
The four sub-groups stratified by HOMAIR1 | Total | ||||
Q1 (327, 25%) | Q2 (326, 25%) | Q3 (328, 25%) | Q4 (327, 25%) | (1308, 100%) | |
Age (yr) | 38.1 ± 10.0 | 38.5 ± 9.7 | 38.7 ± 10.0 | 39.7 ± 10.3 | 38.7 ± 10.0 |
Systolic blood pressure (mmHg) | 124.4 ± 13.9 | 125.8 ± 14.7a | 128.0 ± 15.1a | 132.5 ± 16.0a | 127.7 ± 15.2 |
Diastolic blood pressure (mmHg) | 77.3 ± 10.0 | 77.6 ± 10.4a | 79.6 ± 11.2a | 82.1 ± 11.7a | 79.1 ± 11.0 |
Body mass index (kg/m2) | 22.8 ± 2.5 | 23.7 ± 2.5a | 25.1 ± 2.7a | 27.0 ± 3.4a | 24.7 ± 3.3 |
Waist circumference (cm) | 83.6 ± 6.6 | 85.8 ± 6.1a | 88.9 ± 6.7a | 92.6 ± 7.5a | 87.7 ± 7.5 |
ALT (U/L) | 22.4 ± 16.1 | 25.5 ± 18.1a | 36.1 ± 48.4a | 40.2 ± 26.4a | 31.0 ± 31.0 |
AST (U/L) | 23.9 ± 11.1 | 24.2 ± 16.0a | 27.6 ± 20.2a | 28.0 ± 11.5a | 25.9 ± 15.3 |
Fasting glucose (mg/dL) | 95.1 ± 7.6 | 97.9 ± 7.9a | 99.4 ± 7.9a | 102.5 ± 8.5a | 98.7 ± 8.4 |
Fasting insulin (U/mL) | 3.6 ± 1.0 | 6.1 ± 0.9a | 8.9 ± 1.1a | 15.8 ± 6.5a | 8.6 ± 5.7 |
HOMAIR | 0.8 ± 0.2 | 1.5 ± 0.2a | 2.1 ± 0.2a | 3.9 ± 1.7a | 2.1 ± 1.5 |
Triglyceride (mg/dL) | 113.9 ± 86.8 | 127.6 ± 86.2a | 157.9 ± 105.7a | 202.8 ± 156.9a | 150.6 ± 117.6 |
HDL (mg/dL) | 52.8 ± 12.5 | 50.2 ± 9.8a | 47.4 ± 10.7a | 44.4 ± 8.9a | 48.7 ± 11.0 |
Table 2 Abnormality prevalence distribution, stratified by HOMAIRn (%)
The four sub-groups stratified by HOMAIR | Total | ||||
Abnormality1 | Q1 327 (25) | Q2 326 (25) | Q3 328 (25) | Q4 327 (25) | 1308 (100) |
Obesity | 20 (6.1) | 29 (8.9) | 81 (24.7)a | 153 (46.8)a | 283 (21.6) |
Elevated ALT | 25 (7.6) | 36 (11.0) | 74 (22.6)a | 118 (36.1)a | 253 (19.3) |
Metabolic syndrome components | |||||
Abdominal obesity | 45 (13.8) | 74 (22.7)a | 126 (38.4)a | 188 (57.5)a | 433 (33.1) |
Elevated blood pressure | 110 (33.6) | 118 (36.2) | 136 (41.5)a | 187 (57.2)a | 551 (42.1) |
Elevated fasting glucose | 16 (4.9) | 22 (6.7) | 37 (11.3)a | 62 (19.0)a | 137 (10.5) |
Elevated triglyceride | 58 (17.7) | 83 (25.5)a | 132 (40.2)a | 195 (59.6)a | 468 (35.8) |
Hypo-HDL cholesterolemia | 39 (11.9) | 47 (14.4) | 71 (21.6)a | 108 (33.0)a | 265 (20.3) |
Alcohol consumption | 83 (25.4) | 56 (17.2) | 74 (22.6) | 73 (22.3) | 286 (21.9) |
Cigarette smoking | 122 (37.3) | 118 (36.2)a | 108 (32.9) | 109 (33.3) | 457 (34.9) |
Table 3 OR of risk factors, presented as OR (95% CI)
Model1 | Model 1 | Model 2 | Model 3 |
Both obesity and elevated ALT | - | - | 4.3 (2.7-6.8) |
Obesity | 2.52 (1.7-3.6) | 3.02 (2.1-4.2 ) | - |
Elevated ALT | 2.12 (1.4-3.0) | 2.12 (1.5-2.9) | - |
Metabolic syndrome | - | 2.62 (1.8-3.7) | 3.6 (2.6-5.0) |
Abdominal obesity | 1.62 (1.2-2.2) | - | - |
Elevated blood pressure | 1.72 (1.2-2.4) | - | - |
Elevated fasting glucose | 2.82 (1.8-4.4) | - | - |
Elevated triglyceride | 2.22 (1.6-3.1) | - | - |
Hypo-HDL cholesterolemia | 1.62 (1.1-2.2) | - | - |
Alcohol consumption | 1.2 (0.8-1.7) | 1.2 (0.8-1.6) | 1.2 (0.9-1.7) |
Cigarette smoking | 0.9 (0.7-1.2) | 0.9 (0.6-1.2) | 0.9 (0.6-1.2) |
Table 4 Synergistic effect of obesity and elevated ALT on insulin resistance1
OR | (95% CI) | SI | 95% CI | |
Neither obesity nor elevated ALT | 1.0 | Reference | No risk | - |
Obesity only | 2.3 | (1.5-3.5) | One risk only | - |
Elevated ALT only | 1.8 | (1.1-2.9) | One risk only | - |
Obesity plus elevated ALT | 5.5 | (3.2-9.3) | 2.1 | (1.01-4.3) |
- Citation: Chen PH, Chen JD, Lin YC. A better parameter in predicting insulin resistance: Obesity plus elevated alanine aminotransferase. World J Gastroenterol 2009; 15(44): 5598-5603
- URL: https://www.wjgnet.com/1007-9327/full/v15/i44/5598.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.5598